Lv11
74 积分 2024-03-26 加入
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
2小时前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
2小时前
已完结
Dual activation of MC3R and MC4R drives weight loss and reduces food intake in male primates with obesity
3天前
已完结
Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications
9天前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
15天前
已完结
Design, synthesis and preclinical evaluation of bio-conjugated amylinomimetic peptides as long-acting amylin receptor agonists
18天前
已完结
FGF21 synergizes with leptin to counteract obesity-related metabolic comorbidities by reversing hepatic leptin resistance
18天前
已完结
Survodutide Once Weekly for the Treatment of Adults with Obesity
2个月前
已完结
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2个月前
已完结
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
2个月前
已完结
皖公网安备34019202002308
